← Back to patent-cliff list
CPL-01
Tier C — Watch / tradeCPL-01
Cali Pharmaceuticals Llc
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：SCNA
Indications (approved)：Postoperative pain, 拇囊炎, Inguinal hernia, 拇外翻
Regional status
US
Phase III
2023-04-18
EU
-
China
Phase III
2023-08-31
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of CPL-01?
Approved indications include: Postoperative pain, 拇囊炎, Inguinal hernia, 拇外翻.
When does the CPL-01 patent expire?
No public expiry year is available for CPL-01 yet; this page updates once verified.
How do I get a quote for CPL-01 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-03